A new challenge of unfractionated heparin anticoagulation treatment for moderate to severe COVID-19 in Japan

Rubuna Sato; Masahiro Ishikane; Noriko Kinoshita; Tetsuya Suzuki; Takato Nakamoto; Kayoko Hayakawa; Norifumi Bekki; Hisao Hara; Norio Ohmagari

doi:10.35772/ghm.2020.01044

This article has now been updated. Please use the final version.

A new challenge of unfractionated heparin anticoagulation treatment for moderate to severe COVID-19 in Japan

Rubuna Sato, Masahiro Ishikane, Noriko Kinoshita, Tetsuya Suzuki, Takato Nakamoto, Kayoko Hayakawa, Norifumi Bekki, Hisao Hara, Norio Ohmagari

Author information

Rubuna Sato
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masahiro Ishikane
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Noriko Kinoshita
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Tetsuya Suzuki
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Takato Nakamoto
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Kayoko Hayakawa
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Norifumi Bekki
Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan.
Hisao Hara
Department of Cardiology, National Center for Global Health and Medicine, Tokyo, Japan.
Norio Ohmagari
Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Keywords: COVID-19, hypercoagulation, anticoagulation treatment, unfractionated heparin

JOURNAL FREE ACCESS Advance online publication

Article ID: 2020.01044

DOI https://doi.org/10.35772/ghm.2020.01044

The final version of this article is now available: Vol. 2 (2020), No. 3 pp. 190-192

Details

Abstract

Hypercoagulation and anticoagulation treatment have become new challenges in coronavirus disease 2019 (COVID-19) patients during the COVID-19 pandemic. We herein suggest an algorithm for an anticoagulation treatment with unfractionated heparin in moderate to severe COVID-19 cases in Japan, and report a case of COVID-19 pneumonia with anticoagulation treatment. Although several promising drugs for COVID-19 are being tested in clinical trials, definitive treatments have not yet been established. In this report, we demaonstrate that anticoagulation treatment with unfractionated heparin has the possibility of becoming at least a supportive treatment for COVID-19 patients.

Corresponding author

Register with J-STAGE for free!